Fight For Lipitor: FDA Calls For Dismissal Of Mylan's Plea On Ranbaxy's AIP

MUMBAI - The U.S. Food and Drug Administration has filed for dismissal of Mylan's March 18 motion that sought a declaratory judgement to enforce provisions of the Application Integrity Policy against Ranbaxy, calling for an immediate denial of the ANDA for Pfizer's leading cholesterol-lowering agent Lipitor (atorvastatin) to the Indian company